Recently, news that Shanghai Race plans to acquire Boehringer Ingelheim Biopharmaceutical Co., Ltd., which is owned by Boehringer Ingelheim Investment Co., Ltd., sparked a buzz in the pharmaceutical community. On the afternoon of September 28, Xu Jun, vice chairman and general manager of Shanghai Laishi, responded to reporters about the reason for the acquisition of the factory, saying it was “a strategic card position aimed at complementing the industrialization capacity of innovative drugs.” Xu Jun also said that the company's layout of the innovative drug business is not a “desperate effort.” Innovative drug research and development investment is supported by stable cash flow generated by the blood products business. The company will not invest all profits from the blood products sector into innovative drugs at once, adopting a strategy of rolling investment and doing what it can.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.